Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 3 versions Re-verified since Mar 31, 2023, no change to tracked fieldsv26-v28
  2. Results first posted: May 6, 2019
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study arms: 1 to 5
    • Eligibility criteria expanded, about 2 words
    v25
  3. Primary completion date: Dec 2007 to Mar 3, 2017v24 Show 4 more changesShow less
    • Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 145 to confirmed 68
    • Study completion date changed from estimate of Nov 2018 to Mar 3, 2017
    • Start date: Nov 2005 to Nov 15, 2005
  4. Primary completion date changed from estimate of Nov 2018 to Dec 2007
    • Study completion date: Nov 2018
    v23
  5. Primary completion date: Nov 2016 to Nov 2018v22
Show 20 earlier versionsHide 20 earlier versions
  1. Primary completion date: Nov 2015 to Nov 2016
    • Secondary endpoints: details revised at 1 of 1 entry
    v21
  2. Primary completion date: Nov 2014 to Nov 2015v20
  3. Re-verified, no change to tracked fieldsv19
  4. Primary endpoint revised
    • Eligibility criteria expanded, about 8 words
    v18
  5. Re-verified, no change to tracked fieldsv17
  6. Primary completion date: Nov 2012 to Nov 2014v16
  7. Re-verified, no change to tracked fieldsv15
  8. Study description expanded, about 15 wordsv14
  9. Primary completion date: Nov 2011 to Nov 2012
    • Study description shortened, about 118 words
    v13
  10. Primary completion date: Nov 2010 to Nov 2011v12
  11. 2 versions Re-verified since Jul 26, 2010, no change to tracked fieldsv10-v11
  12. Primary completion date: Dec 2009 to Nov 2010v9 Show 5 more changesShow less
    • Primary endpoint revised
    • Study completion date: Dec 2009 to not stated
    • Eligibility criteria shortened, about 16 words
    • Secondary endpoint revised
    • Study description shortened, about 144 words
  13. Primary completion date: Dec 2009
    • Study completion date: Aug 2009 to Dec 2009
    • Secondary endpoints: details revised at 1 of 1 entry
    v8
  14. Primary endpoints: 3 to 1v7 Show 7 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 2 to 1
    • Study completion date: Aug 2009
    • Interventions: dasatinib (BMS-354825) (Drug) to Dasatinib (BMS-354825) (Drug)
    • Secondary endpoints expanded, about 7 words
    • Study description expanded, about 124 words
    • Study arms: 0 to 1
  15. 2 versions Re-verified since Oct 23, 2006, no change to tracked fieldsv5-v6
  16. Enrollment target: 120 to 145
    • Study description expanded, about 156 words
    v4
  17. Re-verified, no change to tracked fieldsv3
  18. Interventions: desatinib (BMS-354825) (Drug) to dasatinib (BMS-354825) (Drug)
    • Eligibility criteria expanded, about 21 words
    • Study description revised
    • Study title expanded, about 2 words
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.
Trial Details
NCT Number NCT00255346
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Bristol-Myers Squibb
Conditions
(from sponsor)		 Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis, Hypereosinophilic Syndrome, Polycythemia Vera, Mastocytosis, Leukemia, Myelomonocytic, Chronic
Related terms Hypereosinophilic Syndrome, Leukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Mastocytosis, Myelodysplastic Syndromes, Polycythemia Vera, Primary Myelofibrosis
Enrollment 68 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov